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Prevention of Rheumatic Fever and Heart Disease:
Nepalese Experience
Prakash Raj Regmi*, Rosemary Wybery
Kathmandu, Nepal; and Perth, Western Australia, AustraliaABSTRACT
Rheumatic heart disease (RHD) is a major public health problem in Nepal that affects young children and
adolescents. Historically, many young people suffered severe valvular disease and died awaiting heart valve
replacement. For some years, the Nepal Heart Foundation (NHF) advocated for a more comprehensive
program to reduce the burden of RHD. In 2007, the government of Nepal announced funding for an RHD
control program to be implemented by the NHF. The core focus of the program was to deliver antibiotics
for the secondary prophylaxis of RHD. The NHF has developed a program of community awareness, free
medication, RHD register development, health worker training, guideline development, and clinical audit.
These services are being implemented with expanding geographic scope. This paper provides a narrative
overview of the Nepalese experience designing, implementing, and beginning to evaluate this program.
Challenges and successes relevant to register-based programs are highlighted.From the *National Acad-
emy of Medical Sciences
(NAMS), Bir Hospital,
Kathmandu, Nepal;
yTelethon Institute forAcute rheumatic fever (RF) is an immunologically
mediated sequel of group A beta hemolytic streptococcal
(GAS) tonsillopharyngitis [1]. The most common cardiac
manifestations are valvulitis and myocarditis, which can
lead to the chronic valve damage of rheumatic heart disease
(RHD). RHD is estimated to affect more than 15.6 million
people worldwide, cause 233,000 deaths every year, and
contribute to signiﬁcant morbidity in young people [2,3].
The vast majority of cases of RF and RHD occur in
developing countries, including Nepal [4].
The burden of RF and RHD can be controlled through
a program of primary, secondary, and tertiary in-
terventions. RF can be prevented by treating GAS tonsil-
lopharyngitis with antibiotics (primary prevention) or valve
damage can be minimized by administration of prophy-
lactic antibiotics (secondary prevention). Treatment of
symptomatic RHD—including medical therapy and oper-
ative intervention—is considered tertiary intervention. This
paper provides a narrative overview of the Nepalese
experience designing, implementing, and beginning to
evaluate a register-based RHD control program to deliver
secondary prevention.Child Health Research,
Perth, Western Australia,
Australia. Correspondence:
P. R. Regmi (prregmi@
wlink.com.np).
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Nepal is a developing nation in South Asia with a popu-
lation of 30.49 million people [5]. Rural inhabitants make
up 80% of the population; life expectancy at birth is 69.1
years; and 34% of the population are aged 0 to 14 years
[5,6]. Government health spending on health is about 7%
of gross domestic product and more than half of the costs
of health care are paid out of pocket by consumers [7].
Human resources for health are limited and concentrated
in urban settings [8]. Although these challenges areGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 247-252considerable, there is growing momentum for enhancing a
robust primary care system throughout Nepal [9].
BURDEN OF RF AND RHD
Data on the burden of RF and RHD in Nepal is limited.
Most of the studies are school-based and are from the
capital city, Kathmandu. The prevalence of RHD among
schoolchildren of the 5 to 16 years age group is reported to
be 1.0 to 1.35 per 1,000 in different studies [10e13].
Extrapolating throughout Nepal, the Nepal Heart Foun-
dation (NHF) has made an expert estimate of prevalence of
RHD at 2 per 1,000 schoolchildren. On this basis, the NHF
estimates approximately 75,000 RHD patients live
throughout the country [14]. The incidence of RF is esti-
mated to be 15,000 per year [15]. RHD is among the
leading causes of admission to cardiology services and
cardiothoracic surgery [16].
THE NEPAL RF/RHD PREVENTION AND CONTROL
PROGRAM
Historically, the government of Nepal funded heart valve
replacements for low-income RHD patients. Over 300
valve replacements were provided each year, at a cost of
approximately US$3,000 per operation. This tertiary
approach generated lengthy waiting lists and many patients
with end-stage disease died awaiting surgery. The gov-
ernment of Nepal became interested in developing a con-
trol program, which could decrease the morbidity and
mortality in children and represent a more cost-effective
strategy. Advocacy for a comprehensive approach to dis-
ease control was led by the NHF. The NHF was founded in
1988 and now has 37 district ofﬁces throughout the
country [17]. The NHF is a member of the World Heart247
TABLE 2. Elements of the program
1. Epidemiological studies.
2. Awareness activities.
3. Training of health workers.
4. Case detection (heart screening).
5. Registry of RF/RHD patients.
6. Delivery of medicines for secondary prophylaxis.
7. Surveillance system.
8. Evaluation and monitoring.
Abbreviations as in Table 1.
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248Federation and supports the World Heart Federation’s
mission “to unite members and lead the global ﬁght against
RHD through aligning around the WHO-related target
of 25 percent reduction in RF/RHD mortality by 2025
in under 25 year olds” [18]. The Nepal government
announced approximately US$30,000 of funding for an
RHD control program in 2006 [19]. The NHF was con-
tracted to design and implement this program in 2007.
PROGRAM DESIGN
The NHF investigated a number of models for delivering
disease-speciﬁc health care while developing the national
program for control of RF and RHD. In particular,
decisions were required about the relative contribution of
independent disease-speciﬁc activities (vertical) and inte-
gration of RHD care delivery into the broader health system
(horizontal) [20]. The NHF identiﬁed that a purely vertical
approach was prohibitively costly and a purely horizontal
approach lacked the urgent focus needed for reducing RF/
RHD morbidity and mortality. A combination (diagonal
approach) was chosen in order to focus on RHD within the
framework of the existing healthcare system. The RHD
control program is a diagonal partnership between the
government of Nepal and the NHF. As part of this part-
nership, the government of Nepal has included RHD in the
national health program and provides the key antibiotic for
the program free of charge to consumers. The NHF con-
tinues to advocate for including RHD in noncommunicable
disease planning, on the recommendation of the World
Heart Federation [21].
The national RF/RHD prevention and control program
in Nepal has 3 objectives and 8 elements, outlined in
Tables 1 and 2. Activities in some of these elements are
addressed to illustrate some of the successes and challenges
of implementing RHD control activities in a very low
resource setting.
EPIDEMIOLOGICAL STUDIES
The NHF has developed an RF/RHD register and used this
as a resource for improving local descriptive epidemiology.
NHF conducted a retrospective analysis of 4 years of reg-
ister data, including 6,028 patients (June 2007 to October
2011). Of these, 5,356 (88%) had been diagnosed with
RHD and 672 (12%) with RF. Manifestations of RF were
described as arthritis (82%), carditis (60%), SydenhamTABLE 1. Core program objectives
1. Early detection and registration of RF/RHD patients.
2. Establishment of centers for safe administration of BPG
injection for secondary prophylaxis.
3. Establishment of a national strategy for RF/RHD pre-
vention and control with development of RHD control
toolkit.
BPG, benzathine penicillin G; RF, rheumatic fever; RHD, rheumatic
heart disease.chorea (2.8%), subcutaneous nodules (1.8%), and ery-
thema marginatum (1.1%) [22]. This is the only data
available on manifestations of acute RF in Nepalese
patients.AWARENESS FOR RHD CONTROL
Community awareness activities are essential for a suc-
cessful RHD program [23]. Health literacy at baseline in
Nepal has been limited; few schoolchildren, parents, or
teachers were aware that untreated streptococcal throat
infection could lead to RHD [24]. The NHF has conducted
a range of activities to improve awareness about RHD:
putting large hoarding boards throughout the cities;
mobilizing the media; including RHD materials in school
curriculums; showing street dramas; distributing pam-
phlets, posters, and calendars [24]. A telecast of a docu-
mentary ﬁlm on RHD on the national TV channel was
instrumental in raising public awareness about the disease.
Mobilization of celebrities in awareness campaigns was also
applied with good effect. As a result of these activities, the
awareness on RHD increased by 40% (from 8% to 48%) in
schoolchildren and teachers of Nepal [24].TRAINING FOR RHD CONTROL
Health care in Nepal is mainly delivered by paramedics,
who are responsible for overseeing small clinics. Para-
medics are responsible for delivering benzathine penicillin
G (BPG) injections for secondary prevention of RF. How-
ever, many paramedics were unfamiliar with this process
and unwilling to deliver intramuscular injections for pro-
phylaxis. The major goal of paramedic training was to
support paramedics and enable them to provide secondary
prophylaxis at a primary care level. After completing the
training, more than 90% of paramedics who had earlier
refused to inject BPG agreed to do it under the guidance
and supervision of the NHF. Training and support was
critical for achieving the support and engagement of
paramedics. Future NHF training programs are being
considered for community health workers, teachers, ado-
lescents, and mother groups. Education that encourages
people to seek help for a streptococcal throat infection and
treat it with a suitable antibiotic is the next step.GLOBAL HEART, VOL. 8, NO. 3, 2013
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ECHOCARDIOGRAPHIC SCREENING OF
SCHOOLCHILDREN
World Health Organization (WHO) guidelines recommend
screening for RHD in high prevalence settings [25].
Screening for RHD in schoolchildren has been an impor-
tant part of the RHD prevention program in Nepal. The
NHF has screened more than 100,000 schoolchildren be-
tween 2007 and 2012. A 2-stage method has been used:
brief clinical examination and auscultation, followed by
conﬁrmation of the suspected cases with echocardiogra-
phy. NHF have just completed screening 30,000 school-
children in 38 government schools of the Lalitpur district
in Nepal. In this district, the prevalence of RHD was found
to be 1.8 per 1,000 schoolchildren of ages 5 to 16 years
(NHF, unpublished data, May 2013).REGISTERS OF RF/RHD PATIENTS
Register-based programs have been shown to improve the
rates of secondary prophylaxis and decrease the prevalence
of RHD [25e28]. The RHD program in Nepal maintains
registers as a core component of the disease control efforts
[29]. The RHD control program has enrolled hospitals and
health centers at different levels, with progressive imple-
mentation from central, regional, zonal, and district areas.
Gradual expansion to the periphery has made the program
accessible to more and more rural people. Initially, 22 gov-
ernment hospitals participated in the program, but by the
end of April 2013, 35 hospitals were delivering secondary
prophylaxis. These hospitals maintain registers of the
RF/RHD patients and deliver the BPG injections free of cost.
Patients allergic to penicillin receive oral erythromycin, and
patients unable to receive BPG injections receive oral peni-
cillin V. The WHO recommendations for dose and duration
of secondary prophylaxis are applied [25].
Nepal has adopted a 3-tiered system for maintaining
the RF/RHD registry:
1. Hospital register
This is a paper register with details of the RF/RHD
patients: name; age; sex; contacts; diagnosis; clinical
manifestations; echo ﬁndings; medicines delivered;
dose; batch number; results of allergy test; and dates of
BPG injection delivery. All participating hospitals have a
separate register for RF/RHD patients receiving sec-
ondary prophylaxis. These hospitals forward the data to
the national register.
2. National (central) register
All the patients registered in this program and receiving
penicillin nationwide are entered into the National
RF/RHD register, which is maintained at the program
ofﬁce of the NHF. This is paper and database register.
3. Penicillin injection card
A penicillin injection card is issued to all the patients
receiving secondary prophylaxis. This card contains
patient information, diagnosis, batch number, andGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 247-252expiry date of BPG injection that the patient is receiving,
dates of injections given, due date, and signature of
health personnel delivering the injection.
SECONDARY PROPHYLAXIS OF RHD
Secondary prophylaxis requires regular administration of a
long acting antibiotic—generally BPG—to prevent recurrent
GAS infections and RF in patients with a history of RF or
RHD. WHO recommends 1,200,000 IU of BPG every 4
weeks to those with weight 30 kg in most circumstances
[25]. Individuals who have an RF recurrence on this
regime—or in settings where the incidence of RF is partic-
ularly high—should be considered for 3 weekly BPG in-
jections. Three weekly regimes reﬂect concerns that serum
drug levels may fall below a protective level before the fourth
week after administration in some cases [30,31]. Given the
very high burden of RF inNepal, secondary prophylaxiswith
penicillin once every 3 weeks is recommended by the NHF.
An alternative but less effective method is the use of daily
oral penicillin V. Even with optimal patient adherence, the
risk of recurrence is higher in individuals receiving oral
prophylaxis than in those receiving intramuscular benza-
thine penicillin G [32].
The NHF recently conducted an audit of patients
receiving secondary prophylaxis from the RF/RHD regis-
ters. In a period from June 2007 to February 2010 in 35
hospitals, there were 4,712 patients receiving 3 weekly
injections of BPG: 2,540 (53.9%) female patients and 2,172
(46.1%) male. Diagnosis was RF in 665 (14.1%) and RHD
in 4,047 (85.9%). Of those, 1,728 (36.7%) were younger
than 18 years age and 2,994 (63.3%) were older than 18
years. Out of 4,712 patients, there were 286 (6.0%) de-
faulters who had missed more than 2 consecutive doses of
BPG injections. Reasons for dropout were reported as in-
jection phobia (4.9%), prohibitive distance (0.8%), pro-
hibitive cost (0.2%), and other (0.3%). Compliance to
secondary prophylaxis was calculated to be 89.3% (NHF,
unpublished data, March 2012).
HURDLES TO SECONDARY PROPHYLAXIS
The NHF has identiﬁed a number of speciﬁc challenges in the
early days of the secondary prophylaxis program
implementation.
Reluctance to administer BPG
The predominant challenge of the program has been the
reluctance of paramedics to administer BPG for fear of
anaphylaxis. Paramedics were particularly concerned about
community reaction following adverse drug reactions;
anecdotal reports suggested some health workers had
suffered physical assault, claims for ﬁnancial compensa-
tion, and jail sentences following deaths. Overcoming these
concerns was the most difﬁcult part of the program.
Paramedics involved in the RHD prevention program were
provided with training on penicillin skin testing and safe
penicillin delivery, which increased their knowledge and249
TABLE 4. NHF recommendations on safe benzathine penicillin
injection delivery
1. Take consent from the patient or his/her relative before
the ﬁrst penicillin injection, with change in batch number
and brand.
2. Record the brand name and batch number of the BPG.
3. Reconstitute the BPG powder with 3.5 ml of sterile
distilled water.
4. Use 2 separate needles: 1 for pricking the vial and the
other for injecting into the patient.
5. Use 10ml syringe and 21-G needle for deep intramuscular
injection.
6. Patient should lie down on trolley or bed on abdomen
with head resting on pillow in a comfortable and relaxed
position. In hospital settings, bed should be portable to
rush the patient to the intensive care unit in case of
emergency.
7. Inject BPG deep intramuscularly in the upper outer
quadrant of the buttock.
8. Stay prepared for the treatment of possible anaphylaxis.
The following medicines and instruments should be
ready for emergency use:
a. Adrenaline injection: l ampoule pre-loaded into the
syringe.
b. Atropine injection.
c. Dexamethasone or antihistamine injection.
d. Intubation set.
e. Suction machine.
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penicillin skin testing (Table 3) and safe penicillin injection
delivery (Table 4). This was of great practical use to the
paramedics. It also became apparent that paramedics were
also struggling to differentiate between anaphylactic re-
actions and vasovagal reactions. Providing training about
the difference of these conditions and management
approach was considered very helpful (Table 5).
Pain of injection
Another major issue that affected the compliance to peni-
cillin injection was the injection pain. Nearly 5% of patients
on secondary prophylaxis stopped taking BPG injections
due to pain (NHF, unpublished data). The NHF developed
recommendations for pain reduction (Table 6).
Concerns about BPG quality
BPG appears on the WHO essential medicines list and on
the Nepal national list [33,34]. Supplies for the national
RHD control program are provided by the government of
Nepal. There are no local manufacturers and all BPG
supplies are imported from India. Three brands of BPG are
available in Nepal: Penidure LA (Wyeth, Madison, New
Jersey); Pencom (Alembic, Gujarat, India); and Longacillin
(Hindusthan Antibiotic, Pimpri, India). Anecdotal concerns
about quality have been reported for all manufacturers. Of
the 3 options, paramedics were most satisﬁed with Pen-
idure LA, because they felt it was easy to reconstitute, had
less clogging, and fewer allergic reactions. More quality
concerns were reported during the period when Wyeth
discontinued manufacturing Penidure LA and Pencom was
substituted [35]. This appeared to be associated with more
minor allergic reactions and blocking of the needle during
injection [35]. The association between brand and fre-
quency of adverse drug reaction is concerning for theTABLE 3. NHF recommendations on penicillin skin testing
1. Perform penicillin allergy skin test in the following
situations:
a. Before ﬁrst penicillin injection.
b. With change in batch number.
c. With change in brand name.
2. Steps for penicillin skin test:
a. Use 23-G needle.
b. Clean the middle of forearm with spirit swab.
c. Inject 0.1 ml of diluted BPG intradermal on the
forearm.
d. Wait for 15 to 20 min.
e. Look for local signs and symptoms of allergy (e.g.,
redness, inﬂammation, itching, erythema, swelling,
blistering).
f. If any of the local signs are present and if the swelling
is >10 mm, the test is considered positive.
BPG, benzathine penicillin G.manufacturing process of BPG. A safe, reliable, and high-
quality supply of BPG is critical for the continued conﬁ-
dence of patients, paramedics, and the community.
Research to support this goal is urgently needed.
STRATEGIES FOR ADDRESSING BARRIERS
Penicillin injection delivery rooms
One of the objectives of the NFH program was to establish
centers for safe delivery of injection BPG. Hospitals with
large numbers of patients receiving secondary prophylaxisTABLE 5. Signs, symptoms, and treatment of anaphylactic reac-
tion and vasovagal reaction
Anaphylactic
reaction
a. Low blood
pressure
b. Tachycardia
c. Sweating
d. Dizziness
e. Dyspnea
f. Syncope
If not treated
immediately, it may
lead to death.
Treat anaphylaxis with
adrenaline injection.
Repeat injection
after 2 to 3 min if
necessary.
Vasovagal
reaction
a. Low blood
pressure
b. Bradycardia
c. Syncope
Treat vasovagal
reaction with
atropine injection.
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TABLE 6. NHF recommendations for minimizing pain of BPG
injections
1. Shake the powdered BPG vial after adding 3.5 ml of
distilled water until the powder dissolves and an opa-
que, viscous, suspension is formed with a ﬁnal volume
of w5.0 ml. The penicillin crystal can easily pass
through a 21- to 23-G needle. If the crystals are
attached to each other, they form large particles that
get clogged inside the needle. To avoid this situation,
reconstitution of the powder with 3.5 ml of distilled
water rather than 3 ml is advised.
2. Use 21-G taper cut needle for intramuscular injection.
3. Properly select the injection site and apply ﬁnger
pressure for 10 s.
4. Stretch the skin at the injection site with the thumb and
index ﬁnger.
5. Inject the liquid medicine at 90 angle with taper cut
needle tip facing downward in vertical plane, which will
cause minimum nerve end damage.
6. Never double prick with the same needle.
7. Push the syringe slowly, applying sufﬁcient pressure in
a gradually increasing manner to allow the crystals in
the viscous medicine to ﬂow smoothly. It may take up
to 1 min to push 5.0 ml of solution.
8. Distract the attention of the patient away from the
injection.
9. Maintain the injection delivery room temperature
below 30C. In hot air and moist skin, the injections are
more painful.
10. Apply ice pack in case of pain immediately after
injection.
11. Mix 0.5 to 1.0 ml of 1% lignocaine with the BPG solu-
tion for reducing pain if all other techniques fail.
BPG, benzathine penicillin G.
gREVIEWjwere advised to have a separate room dedicated only for
penicillin injection delivery. Hospitals with smaller
numbers of RHD patients could use the same room for
injections and dressings. The RHD control program had to
put forth tremendous efforts to establish penicillin injec-
tion delivery rooms for safe and smooth injection admin-
istration and managing anxiety for paramedics and for
patients. Recommendations were developed to standardize
the process, maximize safety, and minimize pain. Staff were
trained to recognize and treat adverse drug reactions.
Rooms were equipped with an emergency care kit box
containing medication and equipment to manage anaphy-
laxis. Recommendations for a model penicillin injection
delivery room were developed to include patient trolley,
oxygen cylinder, IV stand, suction machine, intubation set,
and emergency care kit with necessary medicines.Penicillin allergy and penicillin skin testing
The incidences of allergic and anaphylactic reactions to
BPG injections are reported to be 3.2% and 0.2%,GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 247-252respectively, and fatal reactions are rare [36,37]. The risk of
a serious reaction is reduced in children under the age of
12 years and the duration of prophylaxis does not appear
to increase the risk of an allergic reaction [36]. The long-
term beneﬁts of BPG therapy in preventing RF far
outweigh the risk of a serious allergic reaction [25,36].
The NHF audited adverse drug reactions to BPG over
77,300 injections delivered to 4,712 RHD patients for
secondary prophylaxis during the period from June 2007
to February 2010 [35]. Sixty-ﬁve patients (1.4%) had an
adverse drug reaction: 5 were anaphylactic reactions, an
incidence of 0.1% (0.7/10,000 injections); 60 were minor
reactions, an incidence of 1.3%. Ten patients had minor
allergy while receiving new batch of benzathine penicillin
(incidence of 0.2%), and 18 patients had minor allergy
with new brand of injection BPG (change from Penidure
LA to Pencom), an incidence of 0.4%. There were 8
vasovagal reactions (0.16%). No deaths were reported [35].
RHD patients, because of poor cardiac function, may be
more susceptible to vasovagal reactions [36]. All health
workers dispensing secondary prophylaxis need proper
training in performing penicillin skin test and delivery of
intramuscular injection. Training the health workers who
deliver secondary prophylaxis helps improve survival from
anaphylaxis. Mortality from anaphylaxis signiﬁcantly
decreased after the launch of RHD control program inNepal.
There were no standardized guidelines about indications
for skin testing inNepal prior to the advent of the national RF/
RHD control program. Some centers performed skin test
before eachpenicillin injection,whereas others limited the test
to the ﬁrst penicillin injection only. The NHF has published
recommendations on penicillin skin testing [35] (Table 3). In
Nepal, skin testing for allergy is recommended in all patients
who are to receive penicillin injections.
NEXT STEPS FOR RHD CONTROL IN NEPAL
Pilot project on primary prevention of acute RF
The NHF is collaborating with the District Public Health
Ofﬁce, the government of Nepal, and Rotary International
district 3292 to initiate a pilot project on primary prevention
of RF in the Lalitpur district. This region has a population of
400,000 of which 40% are children of 5 to 16 years of age.
The program was launched in July 2013 with 42 primary
health centers participating and paramedic training
completed. Tonsillitis and pharyngitis registers will be
maintained. Developing a protocol for diagnosing GAS has
been challenging; theNHF has decided to treat childrenwith
clinical signs and symptoms, aiming for a ﬁnancially viable
“treat all” approach [38]. One group of patients will receive
amoxicillin 3 daily for 7 days and the other group will
receive azithromycin once for 5 days for sore throat.
CONCLUSIONS
The Nepalese model of a diagonal RF/RHD control pro-
gram illustrates the feasibility of care delivery in very low-
resource settings. The commitment from the government251
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252and the community involvement support program sus-
tainability. Developing an RF/RHD registry, training para-
medics, publishing recommendations and guidelines, and
securing a supply of BPG are signiﬁcant achievements and
advances in practice. The extensive involvement and
coordination by the NHF has been critical for success.
Improving the quality and safety of BPG supplies and
piloting primary prophylaxis are the next steps for disease
control. Comprehensive program evaluation is an ongoing
requirement but there are early signs of enormously valu-
able progress.
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